首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group
【2h】

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

机译:化脓性肺炎/反痤疮:优化治疗的实用框架– HS ALLIANCE工作组的系统评价和建议

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hidradenitis suppurativa (HS)/acne inversa is a debilitating chronic disease that remains poorly understood and difficult to manage. Clinical practice is variable, and there is a need for international, evidence‐based and easily applicable consensus on HS management. We report here the findings of a systematic literature review, which were subsequently used as a basis for the development of international consensus recommendations for the management of patients with HS. A systematic literature review was performed for each of nine clinical questions in HS (defined by an expert steering committee), covering comorbidity assessment, therapy (medical, surgical and combinations) and response to treatment. Included articles underwent data extraction and were graded according to the Oxford Centre for Evidence‐based Medicine criteria. Evidence‐based recommendations were then drafted, refined and voted upon, using a modified Delphi process. Overall, 5310 articles were screened, 171 articles were analysed, and 65 were used to derive recommendations. These articles included six randomized controlled trials plus cohort studies and case series. The highest level of evidence concerned dosing recommendations for topical clindamycin in mild disease (with systemic tetracyclines for more frequent/widespread lesions) and biologic therapy (especially adalimumab) as second‐line agents (following conventional therapy failure). Good‐quality evidence was available for the hidradenitis suppurativa clinical response (HiSCR) as a dichotomous outcome measure in inflammatory areas under treatment. Lower‐level evidence supported recommendations for topical triclosan and oral zinc in mild‐to‐moderate HS, systemic clindamycin and rifampicin in moderate HS and intravenous ertapenem in selected patients with more severe disease. Intralesional or systemic steroids may also be considered. Local surgical excision is suggested for mild‐to‐moderate HS, with wide excision for more extensive disease. Despite a paucity of good‐quality data on management decisions in HS, this systematic review has enabled the development of robust and easily applicable clinical recommendations for international physicians based on graded evidence.
机译:化脓性Hidradenitis(HS)/反痤疮是一种使人衰弱的慢性疾病,至今知之甚少且难以治疗。临床实践是多种多样的,因此需要关于HS管理的国际,基于证据且易于应用的共识。我们在这里报告了系统的文献综述的发现,这些发现随后被用作制定国际共识建议以治疗HS患者的基础。对HS(由专家指导委员会定义)中的9个临床问题中的每一个进行了系统的文献综述,涵盖合并症评估,治疗(药物,手术和组合)以及对治疗的反应。纳入的文章经过数据提取,并根据牛津循证医学中心的标准进行分级。然后使用改进的Delphi流程起草,完善和表决基于证据的建议。总共筛选了5310篇文章,分析了171篇文章,并使用65篇来提出建议。这些文章包括六项随机对照试验以及队列研究和病例系列。最高水平的证据涉及在轻度疾病(全身性四环素用于更常见/更广泛的病变)和生物治疗(尤其是阿达木单抗)作为第二线药物(继常规治疗失败之后)的局部克林霉素剂量推荐。高质量的证据可用于治疗化脓性水肿性水肿的临床反应(HiSCR),作为治疗炎症区域的二分法结果。较低水平的证据支持对轻度至中度HS患者的局部三氯生和口服锌,中度HS患者的全身性克林霉素和利福平以及静脉内厄他培南的建议。还可以考虑使用Intraesial或全身性类固醇。建议对轻度至中度HS进行局部手术切除,对于更广泛的疾病建议广泛切除。尽管HS的管理决策缺乏高质量的数据,但这项系统的审查仍能够根据分级证据为国际医生制定可靠且易于应用的临床建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号